SEC Form 4 · accession 0000899243-17-005889
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roy Doumani
Director
Period of report
Mar 1, 2017
Accepted (ET)
Mar 2, 2017 · 6:06 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 1, 2017 | S | 10,000 | $72.2673 | D | 121,017 | D | |
| Common Stock | Mar 1, 2017 | S | 6,000 | $77.0334 | D | 115,017 | D | |
| Common Stock | Mar 1, 2017 | S | 2,800 | $76.765 | D | 25,065 | I | By spouse |
| Common Stock | Mar 1, 2017 | M | 50,000 | $1.35 | A | 75,065 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $1.35 | Mar 1, 2017 | M | 50,000 | D | — | Mar 24, 2024 | Common Stock | 50,000 | 75,065 | D |
Explanation of responses
- F11/36th of the shares subject to the stock option vested immediately, and the remaining shares vested in 35 equal monthly installments commencing March 31, 2014.